|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
4/2022
vol. 124 abstract:
Case report
Observation of changes in the eye and joints due to the modification of therapy for ankylosing spondylitis and recurrent uveitis – a twenty-year follow-up study
Bernadetta Płatkowska-Adamska
1, 2
,
Magdalena Kal
1, 2
,
Ewa Pater
3
,
Maria Maciejowska-Roge
3
,
Jan Biskup
2
,
Michał Biskup
2
,
Dominik Odrobina
1, 4
KLINIKA OCZNA 2022, 124, 4: 245-248
Online publish date: 2022/12/19
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
We present a twenty-year follow-up study of a patient and changes in his eyes and joints under various therapies for ankylosing spondylitis. Sulfasalazine, methotrexate, etanercept and adalimumab were used to treat the systemic disease. Ophthalmological treatment of recurrent uveitis occurring every 2 months included intravenous dexamethasone, oral prednisone and topical dexamethasone and 1% tropicamide. Long-term treatment with steroids resulted in complications such as cataracts and herpetic keratitis. Prior to treatment with adalimumab, treatment-resistant, recurrent uveitis and complications such as proliferative vitreoretinopathy and secondary retinal detachment resulted in irreversible lesions and blindness in the right eye. By switching the TNF-α inhibitor to adalimumab for rheumatological ailments, the patient achieved significant improvement in visual acuity in the left eye and a long-term absence of inflammatory symptoms in this eye, which confirms that in the case of spondyloarthropathy, the cooperation of a rheumatologist and an ophthalmologist is necessary.
keywords:
ankylosing spondylitis, spondyloarthritis, biological treatment, non-infectious uveitis |
|
POLSKI
